Predictors of adalimumab durability in hidradenitis suppurativa: a multicenter cohort study.

Authors

• Albert T Young
• Arashleen Pannu
• Alexander Velaoras
• Roland Leyson
• Rayad B Shams
• Alexandra Turfe
• Andrea Dai
• Mohsen Mokhtari
• Sarah Bassett
• Joshua Vazhappilly
• Richard Hass
• Iltefat Hamzavi
• Christopher J Sayed
• Qing-Sheng Mi
• Sherry Yang

Publication/Presentation Date

12-1-2026

Abstract

BACKGROUND: Adalimumab is widely used for hidradenitis suppurativa (HS), but treatment durability varies and predictors of sustained benefit remain uncertain.

OBJECTIVE: To identify clinical and laboratory factors associated with adalimumab treatment durability in HS.

METHODS: We retrospectively studied 135 adults with HS who initiated adalimumab as first biologic therapy across three academic centers from 2013 to 2023. Outcomes were categorized as primary failure (12-24 weeks), secondary failure (24 weeks-2 years), or sustained response (>2 years) based on discontinuation for inefficacy. Predictors of treatment durability were evaluated using ordinal logistic regression.

RESULTS: In univariable analyses, Hurley stage 3, higher body mass index, diabetes, and lower hemoglobin were associated with lower adalimumab durability. In the multivariable model, Hurley stage 3 remained independently associated with less favorable durability (adjusted odds ratio 0.37, 95% confidence interval 0.17-0.81). Comorbid psoriasis was not significantly associated with durability (adjusted odds ratio 2.84, 95% confidence interval 0.96-8.39). Baseline laboratory parameters, including leukocyte and monocyte counts and albumin, did not predict outcome. Age at disease onset, disease duration, and other demographic characteristics were also not associated with durability.

CONCLUSION: Hurley stage 3 was independently associated with lower adalimumab durability, while routinely available laboratory measures did not identify additional predictors of long-term treatment outcome.

Volume

37

Issue

1

First Page

2719076

Last Page

2719076

ISSN

1471-1753

Published In/Presented At

Young, A. T., Pannu, A., Velaoras, A., Leyson, R., Shams, R. B., Turfe, A., Dai, A., Mokhtari, M., Bassett, S., Vazhappilly, J., Hass, R., Hamzavi, I., Sayed, C. J., Mi, Q. S., & Yang, S. (2026). Predictors of adalimumab durability in hidradenitis suppurativa: a multicenter cohort study. The Journal of dermatological treatment, 37(1), 2719076. https://doi.org/10.1080/09546634.2026.2719076

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

42619449

Department(s)

Administration and Leadership

Document Type

Article